[1] CHEN TingLI JialongBAI RuiSHI Xiaoyan?DUAN LifangLI CuijuanFAN Yu,.Inhibitory Effect and Mechanism of Huachansu on Drug Resistance in HepG2/ADM Cells [J]. Modern Traditional Chinese Medicine, 2024, (01): 89-94. [doi: 10.13424/j.cnki.mtcm.2024.01.019]
Inhibitory Effect and Mechanism of Huachansu on Drug Resistance in HepG2/ADM Cells
- Article number:
- 1672-0571(2024)01-0089-06
- Keywords:
- Key words:Huachansu; Multidrug resistance; Human liver cancer cells HepG2/doxorubicin; Bcl-2/Bax; Apoptosis
- ZTFLH:
- R285.5
- Code:
- A
- Abstract:
- Abstract：Objective To observe the effect of Huachansu on the drug resistance of human liver cancer cells HepG2/doxorubicin (ADM) and its possible mechanism of action.Methods HepG2 and HepG2/ADM cells were treated with different concentrations of bufalin for 24 hours，and the cell proliferation inhibition rate was detected by MTT assay.The half inhibitory concentration (IC50) was calculated；Observing cellular morphological changes under an inverted microscope；The impact of drug accumulation experiments on intracellular drug accumulation；Western blot assay was used to detect the expression of apoptosis related proteins Bcl-2，Bax，Caspase-9，and Caspase-3.Results The results showed that Huachansu can inhibit the proliferation of HepG2 and HepG2/ADM cells，with a resistance multiple of 4.67；As the concentration of Huachansu increased，the volume of HepG2/ADM cells decreased，the number of cell wrinkled processes decreased，and the intercellular connections decreased；Compared with the drug resistant group，Huachansu can increase the accumulation level of doxorubicin in HepG2/ADM cells，upregulate the expression of Bax，Caspase-9，and Caspase-3 proteins (P＜0.05)，and downregulate the expression of Bcl-2 protein (P＜0.01)，promoting cell apoptosis.Conclusion Huachansu can significantly inhibit the proliferation of HepG2/ADM cells，increase the accumulation of ADM in cells，and its mechanism of action may be related to regulating the expression of Bcl-2/Bax protein and inducing cell apoptosis.
References:
［1］Sung H，Ferlay，J，Siegel，et al.Global Cancer Statistics 2020：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries［J］.CA-CANCER J CLIN，2021，71 (3)：209-249.
［2］Song T,Lang M,Ren S,et al.The past,present and future of conversion therapy for liver cancer［J］.Am J Cancer Res,2021,11(10):4711-4724.
［3］陈建国,张永辉,陆建华,等.中国肝癌预防与筛检工作实践及防控挑战［J］.中国肿瘤,2023,32(11):836-847.
［4］余云霞，夏嘉文，熊友香.中药逆转肝癌多药耐药机制的研究进展［J］.上海中医药杂志，2019，53(8)：92-97.
［5］Vaidya FU，Sufiyan Chhipa A，Mishra V，et al.Molecular and cellular paradigms of multidrug resistance in cancer［J］.Cancer Rep (Hoboken)，2022，5（12）：e1291.
［6］Zhang L,Ye BW,Chen Z,et al.Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers［J］.Acta Pharmaceutica Sinica B,2023,13(3):982-997.
［7］Emran TB,Shahriar A,Mahmud AR,et al.Multidrug resistance in cancer:understanding molecular mechanisms,immunoprevention and therapeutic approaches［J］.Frontiers in Oncology,2022,12:891652.
［8］Lei ZN,Tian Q,Teng QX,et al.Understanding and targeting resistance mechanisms in cancer［J］.MedComm,2023,4(3):e265.
［9］汤嵩，江啸，王翔，等.原发性肝癌多药耐药相关机制的研究进展［J］.中国肿瘤临床与康复，2018，25(8)：1020-1024.
［10］Baguley，BC.Multiple drug resistance mechanisms in cancer［J］.MOL BIOTECHNOL，2010，46（3）：308-306.
［11］高洁，贾翌江，阿依江，等.肿瘤多药耐药机制及逆转耐药研究进展［J］.现代肿瘤医学，2022，30(21)：3991-3995.
［12］王琛，白桦，肖慧，等.华蟾素胶囊联合α干扰素对原发性小肝癌患者术后免疫功能和远期预后的影响［J］.世界临床药物，2022，43(5)：554-558，564.
［13］徐晓华，吴煜，移康军，等.华蟾素注射液联合肝动脉化疗栓塞治疗肝癌的系统评价再评价［J］.中国中医药信息杂志，2022，29(4)：27-33.
［14］Fanghua Q，Jinjing W，Lim Z，et al.Cinobufacini inhibits epithelial-mesenchymal transition of human hepatocellular carcinoma cells through c-Met/ERK signaling pathway［J］.BIOSCI TRENDS.2018，12 (3)：291-297.
［15］Xia，J，Inagaki，Y，Gao，J，et al.Combination of Cinobufacini and Doxorubicin Increases Apoptosis of Hepatocellular Carcinoma Cells through the Fas- and Mitochondria-Mediated Pathways［J］.AM J CHINESE MED.2017，45 (7)：1537-1556.
［16］李朝阳.华蟾素胶囊联合PC化疗方案治疗晚期非鳞状非小细胞肺癌患者的效果［J］.中国民康医学，2023，35(6)：32-35，39.
［17］武伟龙.华蟾素注射液联合长春瑞滨+顺铂化疗方案治疗晚期非小细胞肺癌的疗效［J］.慢性病学杂志，2022，23(11)：1718-1720，1723.
［18］徐泳，韩迪，冯凡超，等.华蟾素注射液联合含铂一线化疗方案治疗非小细胞肺癌的Meta分析［J］.中国中药杂志，2019，44(21)：4728-4737.
［19］于恒旺.华蟾素胶囊联合吡柔比星治疗晚期乳腺癌的临床观察［J］.中国社区医师，2022，38(6)：37-39.
［20］焦阳.华蟾素胶囊联合GP化疗方案治疗晚期乳腺癌的效果观察［J］.临床医学，2021，41(11)：113-115.
［21］肖聪，张懿敏，孙圣荣.华蟾素联用顺铂对乳腺癌 MDA-MB-231细胞活力、凋亡及周期分布的影响［J］.中国医药导报，2019，16(21)：12-16.
［22］孔冰，左明荣，刘艳辉．华蟾素抗胶质瘤的作用及机制研究［J］.四川大学学报(医学版)，2018，49(3)：388-393．
［23］Efuet，ET，Ding，et al.Huachansu mediates cell death in non-Hodgkins lymphoma by induction of caspase-3 and inhibition of MAP kinase［J］.INT J ONCOL，2015,47 (2)：592-600.
［24］叶映泉，李庆林，朱耀东，等.华蟾素抗肿瘤作用机制研究进展［J］.中药药理与临床，2022，38(3)：215-221.
［25］李俊杰，邬海峰，张东明，等.华蟾素体外抑制胆囊癌GBC-SD细胞增殖与侵袭的机制研究［J］.中国当代医药，2021，28(31)：27-32，241.
［26］王旭.GCS参与调控维拉帕米逆转胃癌化疗多药耐药的作用研究［D］.济南：山东大学，2021.
［27］崔羲和，曾蕊，臧远龙，等.瑞香狼毒提取物抗乳腺癌MCF-7细胞多药耐药的研究［J/OL］.中国中药杂志：1-9［2023-04-02］.
［28］李彩琳，吕鸿，张鸿翰，等.美洲大蠊多肽逆转人肝癌HepG2/ADM细胞多药耐药性的作用及机制研究［J］.中草药，2021，52(1)：152-159.
［29］孟晓燕，方凡夫，顾伟.细胞凋亡与肝癌多药耐药的研究进展［J］.现代肿瘤医学，2009，17(7)：1354-1356.
［30］Li，M，Yu，et al.Bufalin exerts antitumor effects by inducing cell cycle arrest and triggering apoptosis in pancreatic cancer cells［J］.TUMOR BIOL，2013，35(3)：2461-2471.
Memo
基金项目：国家级大学生创新创业项目（202110716011）；陕西中医药大学创新团队项目(2019-YL14)；陕西省科技厅项目（2021JM-472）；陕西省教育厅2021年度重点科研计划项目（21JS007）